↑ トップへ ← 戻る

 Drug(薬物リスト) DrugBank | All Description Patterns

   e.g. "Sirolimus", "アダリムマブ"    Synonyms (Drugs) were also searched for.

A B C D E F G H  I  J K L M N O P Q R S T U V W X Y Z other

35 / 1,666 drugs found* Show info (disease name, etc.) on mouse-over.
 No.   DrugBank   薬物名(臨床試験情報から抽出)   KEGG DRUG  KEGG GENES  KEGG PATHWAY   指定難病告示番号
 1   Acetate  76件: 11c acetate; 11c-acetate; 20mg/0.5ml glatiramer acetate; 40 mg glatiramer acetate; [n-trans-3-hexenoyl] human growth hormone releasing factor (1-44) acetate; Abiraterone acetate; Acetate; Bazedoxifene acetate; Betamethasone sodium phosphate/betamethasone acetate (celestone® soluspan®), 30 mg im once a day for four days; Caspofungin acetate; Conventional glucocorticoids (immediate release hydrocortisone, cortisone acetate, prednisone, prednisolone, dexamethasone); Cortisone acetate; Cosyntropin acetate; Cyclophosphamide/glatiramer acetate; Delmitide acetate; Depot leuprolide acetate 3.75 mg; Desmopressin acetate; Desmopressin acetate trihydrate; Dirucotide acetate; Experimental glatiramer acetate; Flecainide acetate; Glatiramer acetate; Glatiramer acetate (copaxone®); Glatiramer acetate (db); Glatiramer acetate (ga); Glatiramer acetate (ga) 40 mg; Glatiramer acetate (ol); Glatiramer acetate 150mg enteric coated tablets; Glatiramer acetate 150mg enteric-coated (gastro-resistant) tablets; Glatiramer acetate 20 mg; Glatiramer acetate 20 mg, with mitoxantrone; Glatiramer acetate 20 mg/0.5 ml; Glatiramer acetate 40 mg; Glatiramer acetate injection with oral cetirizine hydrochloride; Glatiramer acetate with minocycline; Glatiramer acetate, (copaxone®); Glatiramer acetate, ifn-beta 1a (im), ifn-beta 1a (subcutaneous), and ifn-beta 1b; Glatiramer acetate, n-acetylcysteine; Gonadorelin acetate and triptorelin acetate; Human interferon beta-1a and glatiramer acetate; Hydrocortisone sodium acetate; L-lysyl-d-prolyl-l-threonine acetate; Lanreotide acetate; Leuprolide acetate (la); Leuprolide acetate 11.25 mg; Leuprolide acetate 3 month depot; Leuprolide acetate 30 mg; Leuprolide acetate 45 mg; Leuprolide acetate depot; Leuprorelin acetate; Leuprorelin acetate 3.75mg injection; Loestrin (norethindrone acetate and ethinyl estradiol); Loestrin 1.5/30 (1.5 mg norethindrone acetate/30 µg ethinyl estradiol); Luphere depot 3.75mg(leuprolide acetate 3.75mg); Lupron (leuprolide acetate); Macimorelin acetate; Megestrol acetate; Megestrol acetate tablet; Nomegestrol acetate; Phosphate and betamethasone acetate, 2 ml.; Plovamer acetate; Prednisolone acetate; Prednisone acetate; Prednisone acetate tablets; Sodium acetate; Sodium-[o-[(2,6-dichlorophenyl)-amino]-phenyl]-acetate; Sotrastaurin (inn) acetate; Tetracosactide acetate; Tocopherol acetate; Tocopheryl acetate; Triptorelin acetate and gonadorelin acetate; Ulipristal acetate; Zinc acetate; Zinc acetate (20mg/d); Zinc acetate dihydrate; Zuretinol acetate;   -   -   -   40件:
1,
2,
6,
10,
13,
35,
40,
46,
49,
51,
60,
64,
70,
71,
73,
75,
76,
78,
81,
83,
85,
86,
88,
90,
96,
97,
113,
145,
156,
162,
171,
206,
222,
224,
225,
235,
265,
288,
298,
299
 2   Azathioprine  33件: 5-asa, prednisone, azathioprine or remicade; Azathioprine; Azathioprine (aza); Azathioprine (aza) or 6-mercaptopurine (6-mp); Azathioprine 25 mg; Azathioprine and allopurinol; Azathioprine in case of endoscopic recurrence; Azathioprine individualised dose; Azathioprine or 6-mercaptopurine; Azathioprine or adalimumab and infliximab; Azathioprine or mesalazine; Azathioprine or methotrexate; Azathioprine or mycophenolate mofetil; Azathioprine weight-based dose; Azathioprine+enteral nutrition; Azathioprine/prednisone; Combination of protein a immunoadsorption, rituximab, dexamethasone plus azathioprine; Continuation of azathioprine; Corticosteroid and azathioprine; Cyclophosphamide, azathioprine,prednisone,methylprednisolone; Cyclophosphamide-prednisone-azathioprine; Early immunosuppressants (azathioprine, methotrexate); Immunosuppressive regime (azathioprine, mycophenolate mofetil or methotrexate); Infliximab and azathioprine combination at week 0; Infliximab and azathioprine combination at week 14; Infliximab with azathioprine (iifx + aza); Infliximab+azathioprine; Infliximab, azathioprine; Overencapsulated azathioprine (imuran) 50 mg tablet; Prednisone - azathioprine; Products containing azathioprine or 6-mercaptopurine; Rituximab (rtx) and azathioprine (aza); Steroids plus azathioprine;   D00238
 D03033 
 -   -   18件:
11,
13,
19,
35,
42,
43,
44,
45,
46,
49,
65,
66,
85,
94,
95,
96,
97,
162
 3   Carboxymethylcellulose  1件: Carboxymethylcellulose;   D07622   -   -   2件:
35,
162
 4   Ciclosporin  4件: Aerolised liposomal ciclosporin a; Ciclosporin; Ciclosporin (ciclosporinium); Ciclosporin a;   D00184   5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2   30件: Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway   44件:
11,
14,
19,
20,
26,
28,
36,
38,
39,
40,
41,
42,
45,
46,
49,
50,
53,
55,
56,
58,
60,
61,
62,
63,
64,
65,
90,
95,
97,
113,
162,
164,
222,
223,
226,
228,
234,
269,
274,
283,
284,
285,
302,
326
 5   Clobetasol  7件: Clobetasol; Clobetasol 0.05% ointment; Clobetasol 0.05% topical ointment; Clobetasol propionate; Clobetasol propionate + methotrexate; Clobetasol propionate alone; Clobetasol propionate cream treatment;   D07715   1件: NR3C1   1件: Neuroactive ligand-receptor interaction   2件:
39,
162
 6   Clobetasol propionate  4件: Clobetasol propionate; Clobetasol propionate + methotrexate; Clobetasol propionate alone; Clobetasol propionate cream treatment;   D01272
 D07715 
 1件: NR3C1   1件: Neuroactive ligand-receptor interaction   1件:
162
 7   Collagenase clostridium histolyticum  -  D09596   -   -   1件:
162
 8   Cotton  1件: Cotton;   -   -   -   2件:
35,
162
 9   Cyclophosphamide  48件: Busulfan, cyclophosphamide, antithymocyte globulin; Busulfan, cyclophosphamide, atg; Busulfan, cyclophosphamide, atg, gcsf; Busulfan, cyclophosphamide, thymoglobulin, fludarabine (conditioning regimen); Busulfan, fludarabine, & cyclophosphamide with immunosuppression with atg and cyclosporine.; Campath, fludarabine, cyclophosphamide; Cyclophosphamide; Cyclophosphamide (cy); Cyclophosphamide (cy) (plan 1); Cyclophosphamide (cy) (plan 2); Cyclophosphamide (drug); Cyclophosphamide + pred; Cyclophosphamide 100mg; Cyclophosphamide 150mg; Cyclophosphamide 30; Cyclophosphamide 40; Cyclophosphamide 50mg; Cyclophosphamide 50mg oral tablet; Cyclophosphamide and atg; Cyclophosphamide and steroids; Cyclophosphamide dose level 1; Cyclophosphamide dose level 2; Cyclophosphamide dose level 3; Cyclophosphamide dose level 4; Cyclophosphamide monohydrate; Cyclophosphamide post transplant; Cyclophosphamide(ctx); Cyclophosphamide, azathioprine,prednisone,methylprednisolone; Cyclophosphamide, bortezomib, dexamethasone; Cyclophosphamide, bortezomib, dexamethasone plus daratumumab; Cyclophosphamide, fludarabine; Cyclophosphamide, fludarabine , thymoglobulin; Cyclophosphamide, fludarabine, rabbit atg; Cyclophosphamide, fludarabine, thymoglobulin; Cyclophosphamide,campath ih and tbi; Cyclophosphamide,cyclosporine a; Cyclophosphamide-prednisone-azathioprine; Cyclophosphamide/glatiramer acetate; Fludarabine, cyclophosphamide; Haploidentical hsct using tbi free regimen, ''atg'' with ''post transplant cyclophosphamide''; High-dose cyclophosphamide; Iv cyclophosphamide; Lenalidomide, dexamethasone and cyclophosphamide; Prednisone and cyclophosphamide; Prednisone plus cyclophosphamide; Prednisone, cyclophosphamide; Rituximab and cyclophosphamide iv; Thalidomide, cyclophosphamide and prednisone;   D00287
 D07760 
 -   -   43件:
13,
14,
16,
19,
20,
26,
28,
35,
36,
40,
41,
42,
43,
44,
45,
46,
49,
50,
51,
52,
56,
60,
61,
62,
65,
66,
84,
85,
93,
96,
162,
164,
172,
222,
224,
265,
274,
283,
284,
285,
288,
326,
331
 10   Doxycycline  7件: Antimicrobial therapy: co-trimoxazole or doxycycline; Doxycycline; Doxycycline 100 mg capsules; Doxycycline hyclate; Doxycycline hyclate ph.eur; Interferon beta 1a, oral doxycycline; Treatment with systemic therapy (doxycycline);   D00307
 D02129
 D03903
 D03904
 D07876 
 -   -   15件:
13,
23,
28,
46,
84,
85,
89,
96,
97,
158,
162,
167,
227,
280,
299
 11   Ethanol  7件: Andrographis paniculata (ethanol extract); Ethanol; Ethanol (96 per cent); Ethanol 96% gel; Ethanol 98% solution; Ethanol bp; Ethanol gel;   D00068
 D02798
 D04855
 D06542 
 -   -   49件:
2,
11,
13,
14,
26,
35,
40,
41,
42,
43,
44,
45,
46,
49,
50,
51,
53,
58,
61,
63,
64,
65,
66,
81,
84,
85,
86,
88,
95,
96,
97,
113,
145,
162,
164,
222,
224,
228,
251,
279,
280,
283,
284,
285,
288,
298,
299,
300,
331
 12   Halometasone  1件: Halometasone;   D07202   1件: NR3C1   1件: Neuroactive ligand-receptor interaction   1件:
162
 13   Imatinib  6件: Bevacizumab (avastin) and imatinib mesylate (gleevec); Imatinib; Imatinib mesilate; Imatinib mesylate; Imatinib mesylate (gleevec); Imatinib mesylate 400mg capsule;   D01441
 D08066 
 3件: ABL1, KIT, PDGFRA   32件: Acute myeloid leukemia, Axon guidance, Breast cancer, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Choline metabolism in cancer, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocytosis, ErbB signaling pathway, Focal adhesion, Gap junction, Glioma, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Shigellosis, Viral myocarditis   11件:
13,
28,
34,
35,
46,
51,
85,
86,
87,
89,
162
 14   Infliximab  66件: 99m technetium infliximab; 99mtc-infliximab; Abp 710 - biosimilar to infliximab; Adalimumab and infliximab; Adalimumab, etanercept, golimumab or infliximab; Anti tnf therapy including infliximab; Anti-tnf: infliximab (infusion); Azathioprine or adalimumab and infliximab; Bdmard withdrawal (etanercept, adalimumab, infliximab, certolizumab, golimumab, tozilizumab, abatacept); Biosimilar infliximab; Ct-p13 sc (infliximab); Cyclosporine vs infliximab; Inflectra (infliximab); Infliximab; Infliximab (bcd-055); Infliximab (ifx alone); Infliximab (ifx); Infliximab (inf) + mtx, db; Infliximab (remicade); Infliximab (remicade): 100 mg of lyophilized infliximab; Infliximab + methotrexate (mtx); Infliximab 10 mg/kg; Infliximab 20 mg/kg; Infliximab 3 mg/kg; Infliximab 5 mg/kg; Infliximab 5 mg/kg body weight infused over 2 hours; Infliximab 5 mg/kg every 6 weeks; Infliximab 7 mg/kg every 8 weeks; Infliximab [infliximab biosimilar 3]; Infliximab and adalimumab; Infliximab and azathioprine combination at week 0; Infliximab and azathioprine combination at week 14; Infliximab and mtx; Infliximab biosimilar; Infliximab control; Infliximab group; Infliximab increased dose; Infliximab increased frequency; Infliximab infusion; Infliximab or adalimumab or golimumab or vedolizumab or ustekinumab; Infliximab with azathioprine (iifx + aza); Infliximab+azathioprine; Infliximab, adalimumab, certolizumab pegol; Infliximab, azathioprine; Infliximab, etanercept; Infliximab, etanercept, adalimumab; Infliximab, methylprednisolone, methotrexate; Infliximab-biosimilar; Infliximab-eu; Infliximab-innovator; Infliximab-pfizer; Innovator infliximab; Intravitreal infliximab; Methotrexate + infliximab; Remicade (infliximab); Remicade® (infliximab); Remicaide (infliximab); Remsima (infliximab); Response to infliximab associated with methotrexate; Sb2 (infliximab biosimilar); Sb2 (proposed biosimilar to infliximab); Ta-650 (infliximab); Tnf blockers (infliximab, adalimumab, etanercept); Topical infliximab; Trexan+salazopyrin+oxiklorin+prednisolone + infliximab; Tumor necrosis factor inhibitor (etanercept, infliximab, adalimumab, and golimumab);   D02598   1件: TNF   61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway   23件:
35,
37,
38,
39,
40,
41,
43,
45,
46,
49,
50,
56,
65,
84,
85,
95,
96,
97,
98,
162,
164,
269,
271
 15   Ixekizumab  1件: Ixekizumab;   D10071   1件: IL17A   5件: Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease (IBD), Rheumatoid arthritis, Th17 cell differentiation   4件:
37,
162,
269,
271
 16   Leflunomide  10件: Leflunomide; Leflunomide (permitted, not necessary); Leflunomide 10mg tab; Leflunomide 20 mg tablets (geneva pharmaceutical); Leflunomide 20 mg+prednisone 0.5mg/kg/d; Leflunomide 20mg tab; Leflunomide mylan; Leflunomide(lef); Leflunomide-sulfasalazine-hydroxychloroquine; Non-mtx dmards (e.g. sulfasalazine, leflunomide, bucillamine, tacrolimus, or mizoribin);   D00749   1件: DHODH   2件: Metabolic pathways, Pyrimidine metabolism   10件:
11,
40,
46,
49,
53,
66,
162,
224,
271,
300
 17   Mepolizumab  5件: Mepolizumab; Mepolizumab (a-il-5 antibody); Mepolizumab 100 mg; Mepolizumab 300 mg; Sb-240563 (mepolizumab);   D04923   1件: IL5   13件: Allograft rejection, Asthma, Autoimmune thyroid disease, Cytokine-cytokine receptor interaction, Fc epsilon RI signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Inflammatory bowel disease (IBD), Intestinal immune network for IgA production, JAK-STAT signaling pathway, Pathways in cancer, T cell receptor signaling pathway, Th1 and Th2 cell differentiation   4件:
44,
45,
98,
162
 18   Methotrexate  81件: Abatacept (aba) + methotrexate (mtx), double-blind (db); Abatacept + methotrexate; Adalimumab with methotrexate; Azathioprine or methotrexate; Bms-582949 and methotrexate; Busulfan/fludarabine phosphate/tacrolimus/methotrexate/g-csf; Certolizumab pegol + methotrexate (mtx); Clobetasol propionate + methotrexate; Cp-690,550 + methotrexate; Cyclosporin, methotrexate (gvhd prophylaxis); Early immunosuppressants (azathioprine, methotrexate); Etanercept + methotrexate; Etanercept , methotrexate; Etanercept, methotrexate, prednisolone; Immunosuppressive regime (azathioprine, mycophenolate mofetil or methotrexate); Infliximab + methotrexate (mtx); Infliximab, methylprednisolone, methotrexate; Intrathecal methotrexate; Methotrexate; Methotrexate 'lederle' 2,5mg tablets; Methotrexate 'lederle' 2.5mg tablets; Methotrexate (metoject® prefilled pen); Methotrexate (mtx); Methotrexate + biologic administration; Methotrexate + infliximab; Methotrexate + methylprednisolone; Methotrexate + salazopyrine + hydroxychloroquine administration; Methotrexate - amneal; Methotrexate - dava; Methotrexate - delay; Methotrexate - etanercept - prednisolone arm; Methotrexate - immediate; Methotrexate 2.5 mg; Methotrexate 2.5 mg tablets; Methotrexate 2.5mg tablets; Methotrexate 2.5mg tablets bp; Methotrexate 25 mg; Methotrexate 50mg/ml solution for injection, pre-filled syringe; Methotrexate and folic acid; Methotrexate as methotrexate disodium; Methotrexate bellon; Methotrexate bellon 25mg/ml; Methotrexate capsules; Methotrexate disodium; Methotrexate lachema 5inj. sol; Methotrexate pfizer 2,5 mg tabletter; Methotrexate placebo; Methotrexate plus enbrel or enbrel alone; Methotrexate plus erb-041 for 12 weeks; Methotrexate plus sulfasalazine; Methotrexate pre-filled pen; Methotrexate prefilled pen; Methotrexate prefilled syringe; Methotrexate sodium; Methotrexate sodium 2.5mg tablets; Methotrexate sodium tablets 2.5 mg; Methotrexate treatment; Methotrexate(mtx); Methotrexate(mtx) administration is at the discretion of the rheumatologist and no tradename is fixed by the protocol.; Methotrexate(necessary); Methotrexate*100cpr 2,5mg; Methotrexate, leucovorin and bms-986142; Methotrexate,adalimumab; Methotrexate-lachema; Methotrexate-sulfasalazine-hydroxychloroquine; Methotrexate® 2.5 mg tablets; Mp-435(dose1) + methotrexate; Mycophenolate mofetil,methotrexate; Oral methotrexate; Phase 1: methotrexate; Response to anakinra associated with methotrexate; Response to infliximab associated with methotrexate; Stable weekly dose of methotrexate; Tacrolimus with methotrexate; Tasocitinib plus methotrexate; Tocilizumab + methotrexate(mtx); Tocilizumab+methotrexate(mtx); Tofacitinib with methotrexate; Tofacitinib without methotrexate; Treatment with systemic therapy (methotrexate); Urine samples taken to measure methotrexate and its major metabolite 7-oh-methotrexate level;   D00142
 D02115 
 2件: DHFR, DHFR2   4件: Antifolate resistance, Folate biosynthesis, Metabolic pathways, One carbon pool by folate   33件:
11,
13,
19,
34,
35,
41,
42,
43,
44,
45,
46,
49,
50,
51,
53,
55,
56,
60,
62,
65,
84,
93,
96,
97,
162,
164,
172,
256,
271,
284,
285,
326,
331
 19   Microcrystalline cellulose  -  D00093   -   -   2件:
35,
162
 20   Minocycline  7件: Combination of minocycline and mtx or mtx alone; Glatiramer acetate with minocycline; Lovastatin, then minocycline/lovastatin; Minocycline; Minocycline 100 mg film-coated tablets; Minocycline hydrochloride; Minocycline, then minocycline/lovastatin;   D00850
 D05045 
 -   -   14件:
2,
6,
8,
13,
46,
84,
85,
90,
94,
162,
201,
206,
280,
299
 21   Mitomycin  2件: Mitomycin; Mitomycin c;   D00208   -   -   3件:
94,
162,
329
 22   Mycophenolate mofetil  17件: Azathioprine or mycophenolate mofetil; Cellcept (mycophenolate mofetil); Cyclosporine combine with mycophenolate mofetil; Immunosuppressive regime (azathioprine, mycophenolate mofetil or methotrexate); Mycophenolate mofetil; Mycophenolate mofetil (cellcept); Mycophenolate mofetil (mmf); Mycophenolate mofetil (mmf) 3 g/day; Mycophenolate mofetil 2 g/day; Mycophenolate mofetil [cellcept]; Mycophenolate mofetil orally 1000 mg twice a day (bid); Mycophenolate mofetil plus lower dose of prednisone; Mycophenolate mofetil(mmf); Mycophenolate mofetil, low dose steroid; Mycophenolate mofetil,methotrexate; Prednisolone and mycophenolate mofetil; Prednisone and mycophenolate mofetil;   D00752
 D05094
 D05095 
 2件: IMPDH1, IMPDH2   3件: Drug metabolism - other enzymes, Metabolic pathways, Purine metabolism   32件:
2,
11,
13,
14,
19,
20,
28,
35,
36,
42,
43,
45,
49,
51,
53,
60,
62,
65,
66,
85,
95,
96,
162,
164,
222,
224,
226,
234,
283,
284,
285,
300
 23   Mycophenolic acid  2件: Mycophenolic acid; Mycophenolic acid mofetil;   D05096   2件: IMPDH1, IMPDH2   3件: Drug metabolism - other enzymes, Metabolic pathways, Purine metabolism   34件:
2,
11,
13,
14,
19,
20,
28,
35,
36,
42,
43,
45,
49,
51,
53,
60,
62,
65,
66,
84,
85,
95,
96,
162,
164,
222,
224,
226,
228,
234,
283,
284,
285,
300
 24   Nicotinamide  2件: Nicotinamide; Nicotinamide riboside;   D00036   -   -   8件:
5,
6,
13,
46,
49,
53,
67,
162
 25   Omalizumab  3件: Omalizumab; Omalizumab (xolair); Rituximab combined with omalizumab;   D05251   1件: FCER1A   4件: Asthma, Fc epsilon RI signaling pathway, Phospholipase D signaling pathway, Sphingolipid signaling pathway   6件:
53,
65,
98,
162,
226,
299
 26   Petrolatum  1件: Petrolatum;   D05304
 D05331 
 -   -   3件:
35,
158,
162
 27   Prednisolone  46件: Azd4017 and prednisolone; Conventional glucocorticoids (immediate release hydrocortisone, cortisone acetate, prednisone, prednisolone, dexamethasone); Corticosteroid (prednisolone); Corticosteroid treatment (methylprednisolone or prednisolone); Corticosteroids (prednisone or prednisolone); Etanercept, methotrexate, prednisolone; Glucocorticoid (prednisone or prednisolone); Intravenous methyl prednisolone; Long-circulating liposomal prednisolone; Low dose prednisolone; Medium dose prednisolone; Methotrexate - etanercept - prednisolone arm; Methyl prednisolone; Methylprednisolone or prednisolone; Oral prednisolone; Overencapsulated prednisolone tablets; Paroxetine & prednisolone; Paroxetine hydrochloride 10 & 20 mg and prednisolone 1 mg bp; Peg-liposomal prednisolone sodium phosphate; Prednisolone; Prednisolone & dipyridamole; Prednisolone + mabthera; Prednisolone 1mg tablets; Prednisolone 20 mg; Prednisolone 40 mg; Prednisolone 5 mg; Prednisolone 5mg tablet; Prednisolone acetate; Prednisolone and chlorambucil; Prednisolone and mycophenolate mofetil; Prednisolone and taper; Prednisolone sodium metasulphobenzoate; Prednisolone sodium phosphate; Prednisolone sodium succinate; Prednisolone tablets b.p. 5mg; Prednisolone tablets bp; Prednisolone tablets usp 5 mg; Prednisolone-dipyridamole; Prednisone or prednisolone; Prednisone/prednisolone; Pyridoxine plus prednisolone; Soluble prednisolone tablets; Sulphasalazine + hydroxychloroquine or prednisolone; Trexan+salazopyrin+oxiklorin+prednisolone; Trexan+salazopyrin+oxiklorin+prednisolone + infliximab; Z102 (prednisolone and dipyridamole).;   D00472
 D00980
 D00981
 D00982
 D01239
 D01998
 D02156
 D03301 
 1件: NR3C1   1件: Neuroactive ligand-receptor interaction   38件:
11,
13,
25,
26,
35,
38,
39,
41,
43,
44,
45,
46,
49,
50,
51,
56,
60,
61,
63,
64,
65,
66,
75,
81,
84,
85,
95,
96,
97,
113,
145,
162,
222,
269,
271,
296,
299,
300
 28   Prednisone  57件: 0 mg prednisone; 5 mg prednisone; 5-aminosalicylic acid(5-asa) and/or prednisone; 5-asa, prednisone, azathioprine or remicade; Azathioprine/prednisone; Chinese herb prescription granule plus prednisone; Conventional glucocorticoids (immediate release hydrocortisone, cortisone acetate, prednisone, prednisolone, dexamethasone); Corticosteroids (prednisone or prednisolone); Cyclophosphamide, azathioprine,prednisone,methylprednisolone; Cyclophosphamide-prednisone-azathioprine; Glucocorticoid (prednisone or prednisolone); Granulocyte-colony stimulating factor (g-csf) and prednisone; Hormone (prednisone); Hydroxychloroquine + prednisone; Leflunomide 20 mg+prednisone 0.5mg/kg/d; Methylprednisolone (mp) or prednisone (pred); Mycophenolate mofetil plus lower dose of prednisone; Oral prednisone; Oral prednisone 5mg; Over encapsulated prednisone; Prednisone; Prednisone (and methylprednisolone); Prednisone + inhibace/cozaar; Prednisone - azathioprine; Prednisone 0,5 mg/kg orally on alternate days; Prednisone 15 mg; Prednisone 5 mg; Prednisone 7.5 mg; Prednisone acetate; Prednisone acetate tablets; Prednisone alone; Prednisone and cyclophosphamide; Prednisone and mycophenolate mofetil; Prednisone and ustekinumab treatment; Prednisone arrow 20mg; Prednisone arrow 5 mg; Prednisone capsules; Prednisone discontinuation; Prednisone in full dose; Prednisone or prednisolone; Prednisone plus cyclophosphamide; Prednisone tablets usp, 1 mg; Prednisone tablets usp, 2.5 mg; Prednisone tablets usp, 5 mg; Prednisone tablets, usp; Prednisone therapy and pharmacokinetic; Prednisone treatment; Prednisone, cyclophosphamide; Prednisone, fk506, mmf; Prednisone, methylprednisolone,cyclophosphamides; Prednisone/prednisolone; Rayos (delayed-release prednisone); Sotatercept with prednisone boost; Tacrolimus combined with prednisone; Thalidomide, cyclophosphamide and prednisone; Treatment systemic therapy (prednisone); Treatment with systemic therapy (prednisone);   D00473   1件: NR3C1   1件: Neuroactive ligand-receptor interaction   44件:
2,
11,
13,
14,
26,
35,
40,
41,
42,
43,
44,
45,
46,
49,
50,
51,
53,
61,
63,
64,
65,
66,
81,
84,
85,
86,
95,
96,
97,
113,
145,
162,
164,
222,
224,
228,
251,
283,
284,
285,
288,
299,
300,
331
 29   Prednisone acetate  2件: Prednisone acetate; Prednisone acetate tablets;   D08416   1件: NR3C1   1件: Neuroactive ligand-receptor interaction   6件:
35,
40,
41,
49,
162,
224
 30   Riboflavin  4件: Cofactor supplementation (thiamine, riboflavin, l-carnitine); Riboflavin; Riboflavin sodium phosphate injection; Riboflavin supplementation;   D00050
 D01622
 D01913 
 -   -   9件:
13,
38,
46,
49,
96,
97,
162,
168,
265
 31   Rituximab  52件: Abatacept, rituximab or tocilizumab; Abp 798 - biosimilar to rituximab; Administration of rituximab and methylprednisolone; Alemtuzumab and rituximab; Alemtuzumab, rituximab; Bendamustine, rituximab; Combination of protein a immunoadsorption, rituximab, dexamethasone plus azathioprine; Combined plasma exchange (pex), rituximab, and corticosteroids; Dexamethasone and rituximab; Experimental (non immunosuppressive symptomatic treatment (nist) and rituximab); Gp2013 - a proposed biosimilar rituximab; Idec-c2b8 (rituximab); Immunosuppressive treatment (eg, rituximab); Individualized dose of rituximab; Intravenous rituximab; Mabthera (rituximab); Mabthera or biosimilar rituximab; Mabthera or biosimilar rituximab product; Mabthera® (rituximab); Originator rituximab - rituxan ® or mabthera ®; Rhtpo in combination with rituximab; Rituxan (inn: rituximab), brand name in the united states; Rituxan (rituximab); Rituxan® (rituximab); Rituximab; Rituximab (anti-cd20); Rituximab (arm a); Rituximab (arm b); Rituximab (mabthera® or rituxan®).; Rituximab (mabthera®); Rituximab (rituxan); Rituximab (rtx) and azathioprine (aza); Rituximab - mabthera; Rituximab 1g iv; Rituximab [mabthera/rituxan]; Rituximab [mabthera]; Rituximab and cyclophosphamide iv; Rituximab combined with omalizumab; Rituximab infusion; Rituximab it; Rituximab iv; Rituximab mabthera; Rituximab or rituximab hyaluronidase human; Rituximab, mtx, folic acid; Rituximab, observational study amon patients with active ra; Rituximab-eu+ rituximab-pfizer x 2 courses; Rituximab-pfizer (pf-05280586) x 3 courses; Rituximab-us + rituximab-pfizer x 2 courses; Rituximab/ mabthera; Sait101 (proposed rituximab biosimilar); Standard dose of rituximab; The standard steroid treatment, plasma exchange and rituximab;   D02994   1件: MS4A1   1件: Hematopoietic cell lineage   42件:
11,
13,
14,
17,
35,
36,
43,
44,
45,
46,
49,
50,
51,
52,
53,
56,
60,
61,
63,
64,
65,
66,
83,
84,
85,
86,
93,
94,
96,
97,
162,
222,
223,
229,
256,
271,
283,
284,
285,
288,
300,
331
 32   Silver  1件: Silver;   -   -   -   2件:
35,
162
 33   Simvastatin  11件: Encapsulated simvastatin tablets; Ezetimibe+simvastatin drug combination; Simvastatin; Simvastatin 20mg/5ml oral suspension; Simvastatin 40 mg film-coated tablets; Simvastatin 40mg; Simvastatin alternova; Simvastatin susp.; Simvastatin treatment for 28 days; Simvastatin-ratiopharm; Simvastatin-ratiopharm®;   D00434   1件: HMGCR   4件: AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis   19件:
6,
13,
15,
34,
46,
49,
51,
66,
79,
86,
89,
94,
158,
162,
195,
265,
298,
299,
310
 34   Tripterygium wilfordii whole  -  -   -   -   8件:
46,
66,
67,
96,
162,
222,
224,
271
 35   Ustekinumab  32件: Evaluation of biological predictive factors of clinical response to ustekinumab; Infliximab or adalimumab or golimumab or vedolizumab or ustekinumab; Placebo ustekinumab; Prednisone and ustekinumab treatment; Stelara (ustekinumab); Subcutaneous ustekinumab; Ustekinumab; Ustekinumab (6 mg/kg); Ustekinumab (90 mg); Ustekinumab (approximately 6 mg/kg); Ustekinumab 130 mg iv; Ustekinumab 180 mg; Ustekinumab 1mg/kg (ip); Ustekinumab 3 mg/kg (ip); Ustekinumab 4.5 mg/kg; Ustekinumab 45 mg; Ustekinumab 6 mg/kg; Ustekinumab 6 mg/kg (ip); Ustekinumab 90 mg; Ustekinumab 90 mg (sc) group 1; Ustekinumab 90 mg (sc) group 2; Ustekinumab 90 mg sc q12w; Ustekinumab 90 mg sc q8w; Ustekinumab 90 milligram (mg); Ustekinumab approximately 6 mg/kg (iv); Ustekinumab iv; Ustekinumab iv - nonresponder - ustekinumab 90mg sc (mp); Ustekinumab iv - responder - ustekinumab 90mg sc (mp); Ustekinumab iv infusion; Ustekinumab liquid in prefilled syringe; Ustekinumab sc; Ustekinumab sc injection;   D09214   3件: IL12A, IL12B, IL23A   25件: African trypanosomiasis, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease (IBD), Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus   16件:
13,
37,
41,
46,
49,
50,
53,
56,
65,
84,
93,
96,
97,
162,
269,
271

先頭へ